Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative Behavior
- 11 February 2009
- journal article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 48 (11), 2559-2568
- https://doi.org/10.1021/bi900038p
Abstract
The protease activity of hepatitis C virus nonstructural protein 3 (NS3) is essential for viral replication. ITMN-191, a macrocyclic inhibitor of the NS3 protease active site, promotes rapid, multilog viral load reductions in chronic HCV patients. Here, ITMN-191 is shown to be a potent inhibitor of NS3 with a two-step binding mechanism. Progress curves are consistent with the formation of an initial collision complex (EI) that isomerizes to a highly stable complex (EI*) from which ITMN-191 dissociates very slowly. Ki, the dissociation constant of EI, is 100 nM, and the rate constant for conversion of EI to EI* is 6.2 × 10−2 s−1. Binding experiments using protein fluorescence confirm this isomerization rate. From progress curve analysis, the rate constant for dissociation of ITMN-191 from the EI* complex is 3.8 × 10−5 s−1 with a calculated complex half-life of ∼5 h and a true biochemical potency (Ki*) of ∼62 pM. Surface plasmon resonance studies and assessment of enzyme reactivation following dilution of the EI* complex confirm slow dissociation and suggest that the half-life may be considerably longer. Abrogation of the tight binding and slow dissociative properties of ITMN-191 is observed with proteases that carry the R155K or D168A substitution, each of which is likely in drug resistant mutants. Slow dissociation is not observed with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics.Keywords
This publication has 45 references indexed in Scilit:
- Recent progress in the development of selected hepatitis C virus NS3·4A protease and NS5B polymerase inhibitorsCurrent Opinion in Pharmacology, 2008
- Hepatitis C therapiesNature Reviews Drug Discovery, 2008
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Multiple Determinants Influence Complex Formation of the Hepatitis C Virus NS3 Protease Domain with Its NS4A Cofactor PeptideBiochemistry, 1999
- Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal formProtein Science, 1998
- Complex Formation between the Hepatitis C Virus Serine Protease and A Synthetic NS4A Cofactor PeptideBiochemistry, 1997
- Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor PeptideCell, 1996
- The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding SiteCell, 1996